{"id":7795,"date":"2025-10-22T23:02:24","date_gmt":"2025-10-22T23:02:24","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/10\/22\/moderna-cmv-vaccine-study-failure\/"},"modified":"2025-10-22T23:02:24","modified_gmt":"2025-10-22T23:02:24","slug":"moderna-cmv-vaccine-study-failure","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/10\/22\/moderna-cmv-vaccine-study-failure\/","title":{"rendered":"STAT+: Moderna says key study of its CMV vaccine, expected to be its next big win, failed"},"content":{"rendered":"<p>    STAT+: Moderna says key study of its CMV vaccine, expected to be its next big win, failed<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>Moderna said Wednesday afternoon that its experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial, a significant setback for a company already facing pressure from Wall Street and the federal government.<\/p>\n<p>The CMV vaccine had been the company\u2019s lead program prior to the Covid-19 pandemic. Leadership had repeatedly said it could bring in between $2 billion and $5 billion in peak annual sales. Analysts polled by Visible Alpha forecast peak sales of $1.6 billion for the product.<\/p>\n<p>\u201cIt\u2019s obviously disappointing,\u201d said Stephen Hoge, Moderna\u2019s president, in an interview.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/10\/22\/moderna-cmv-vaccine-study-failure\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Jason Mast and Matthew Herper<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/10\/22\/moderna-cmv-vaccine-study-failure\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Moderna says key study of its CMV vaccine, expected to be its next big win, failed Moderna said Wednesday afternoon that its experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial, a significant setback for a company already facing pressure from Wall Street and the federal government. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2216,2179,2563,2155,2152],"tags":[2150],"class_list":["post-7795","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-breaking-news","category-infectious-disease","category-moderna","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7795"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=7795"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7795\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=7795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=7795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=7795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}